By Donato Paolo Mancini
Roche Holding AG (ROG.EB) said Thursday that it will present new data for its Ocrevus drug that shows how the drug may delay the need for a wheelchair by seven years for people with a type of multiple sclerosis.
Phase 3 data analyses will be presented from June 16 in Lisbon, the company said. The data is from an exploratory analysis of a study on primary progressive multiple sclerosis and shows Ocrevus patients had a 46% reduction in the risk of progressing to a wheelchair compared to the placebo-treated group.
When this is extrapolated, the data indicates the median for multiple sclerosis patients to require a wheelchair is delayed, increasing to 19.2 years for Ocrevus-treated patients compared to 12.1 years for a placebo, the Swiss company said.
Ocrevus is approved in more than 60 countries and has been used to treat 50,000 patients globally. Buoyed by additional approvals, Ocrevus was a key growth driver in the first-quarter, Roche said in April, totaling sales of 479 million Swiss francs ($485 million), CHF443 million of which were in the United States.
Write to Donato Paolo Mancini at firstname.lastname@example.org
(END) Dow Jones Newswires
June 14, 2018 01:41 ET (05:41 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.